
Policies

Hypocritical U.S. Patent 6630507 on CBD Contradicts the Known Benefits of Cannabis and the Long-Known History of Medical Marijuana Use
U.S. Patent 6630507 and the Schedule-One contradiction, a tale of hypocrisy.
U.S. Patent 6630507 and the Schedule-One contradiction, a tale of hypocrisy.
By Barbara Venezia Those who believe they’re on the cutting edge of the medical marijuana bubble are passionate, and in some cases, quite controversial. One
Subscribe to stay up-to-date with the latest weed news
Subscribe to stay up-to-date with the latest weed news